Chemotherapy Induced Anemia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Chemotherapy Induced Anemia – Pipeline Review, H2 2016’, provides an overview of the Chemotherapy Induced Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia

The report reviews pipeline therapeutics for Chemotherapy Induced Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chemotherapy Induced Anemia therapeutics and enlists all their major and minor projects

The report assesses Chemotherapy Induced Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc.

BIOCAD

Chong Kun Dang Pharmaceutical Corp.

Dr. Reddy's Laboratories Limited

Galenica Ltd.

Panacea Biotec Limited

Pfizer Inc.

PharmaEssentia Corporation

PhytoHealth Corporation

Pieris Pharmaceuticals Inc

Sandoz International GmbH

SBI Pharmaceuticals Co., Ltd.

Therapure Biopharma Inc.

Tolero Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Chemotherapy Induced Anemia Overview 8

Therapeutics Development 9

Pipeline Products for Chemotherapy Induced Anemia - Overview 9

Chemotherapy Induced Anemia - Therapeutics under Development by Companies 10

Chemotherapy Induced Anemia - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Chemotherapy Induced Anemia - Products under Development by Companies 15

Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development 16

3SBio Inc. 16

BIOCAD 17

Chong Kun Dang Pharmaceutical Corp. 18

Dr. Reddy's Laboratories Limited 19

Galenica Ltd. 20

Panacea Biotec Limited 21

Pfizer Inc. 22

PharmaEssentia Corporation 23

PhytoHealth Corporation 24

Pieris Pharmaceuticals Inc 25

Sandoz International GmbH 26

SBI Pharmaceuticals Co., Ltd. 27

Therapure Biopharma Inc. 28

Tolero Pharmaceuticals, Inc. 29

Chemotherapy Induced Anemia - Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Combination Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

darbepoetin alfa - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

darbepoetin alfa - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

darbepoetin alfa - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

darbepoetin alfa - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

darbepoetin alfa - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

epoetin alfa - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

epoetin zeta - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

ferric carboxymaltose - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

P-1116 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

PHN-013 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

PRS-080 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

SSS-06 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

TBI-304H - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

TP-0184 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

TP-0413 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

TXA-302 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Chemotherapy Induced Anemia - Dormant Projects 63

Chemotherapy Induced Anemia - Discontinued Products 64

Chemotherapy Induced Anemia - Product Development Milestones 65

Featured News & Press Releases 65

Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H 65

Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia 65

Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health 65

Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology 66

Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting 66

Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology 67

Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 67

Aug 09, 2010: Dr Reddy’s Launches Darbepoetin Alfa For Treatment Of Anemia In India 68

Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world’s first complex biosimilar 68

Jan 07, 2008: Sandoz and Gambro form strategic alliance 69

Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Tables

List of Tables

Number of Products under Development for Chemotherapy Induced Anemia, H2 2016 9

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Chemotherapy Induced Anemia – Pipeline by 3SBio Inc., H2 2016 16

Chemotherapy Induced Anemia – Pipeline by BIOCAD, H2 2016 17

Chemotherapy Induced Anemia – Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 18

Chemotherapy Induced Anemia – Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 19

Chemotherapy Induced Anemia – Pipeline by Galenica Ltd., H2 2016 20

Chemotherapy Induced Anemia – Pipeline by Panacea Biotec Limited, H2 2016 21

Chemotherapy Induced Anemia – Pipeline by Pfizer Inc., H2 2016 22

Chemotherapy Induced Anemia – Pipeline by PharmaEssentia Corporation, H2 2016 23

Chemotherapy Induced Anemia – Pipeline by PhytoHealth Corporation, H2 2016 24

Chemotherapy Induced Anemia – Pipeline by Pieris Pharmaceuticals Inc, H2 2016 25

Chemotherapy Induced Anemia – Pipeline by Sandoz International GmbH, H2 2016 26

Chemotherapy Induced Anemia – Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016 27

Chemotherapy Induced Anemia – Pipeline by Therapure Biopharma Inc., H2 2016 28

Chemotherapy Induced Anemia – Pipeline by Tolero Pharmaceuticals, Inc., H2 2016 29

Assessment by Monotherapy Products, H2 2016 30

Assessment by Combination Products, H2 2016 31

Number of Products by Stage and Target, H2 2016 33

Number of Products by Stage and Mechanism of Action, H2 2016 35

Number of Products by Stage and Route of Administration, H2 2016 37

Number of Products by Stage and Molecule Type, H2 2016 39

Chemotherapy Induced Anemia – Dormant Projects, H2 2016 63

Chemotherapy Induced Anemia – Discontinued Products, H2 2016 64

List of Figures

List of Figures

Number of Products under Development for Chemotherapy Induced Anemia, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Assessment by Monotherapy Products, H2 2016 30

Number of Products by Targets, H2 2016 32

Number of Products by Stage and Targets, H2 2016 32

Number of Products by Mechanism of Actions, H2 2016 34

Number of Products by Stage and Mechanism of Actions, H2 2016 34

Number of Products by Routes of Administration, H2 2016 36

Number of Products by Stage and Routes of Administration, H2 2016 36

Number of Products by Molecule Types, H2 2016 38

Number of Products by Stage and Molecule Types, H2 2016 38

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports